Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2014, vol. 20, issue 6
Subject Collection: Medicine
Pages: 556-559
DOI: 10.5272/jimab.2014206.556
Published online: 23 December 2014

J of IMAB 2014 Oct-Dec;20(6):556-559
Deyan Davidov Corresponding Autor.
Department of Medical Oncology, Oncological Center - UMHAT "Dr Georgi Stranski", Medical University, Pleven, Bulgaria.

Objective: Bevacizumab improved survival when added to chemotherapy for patients with metastatic colorectal cancer (mCRC). The aim of this study was to explore the efficacy and safety of Bevacizumab containing chemotherapy regimen in the treatment of patient with mCRC.
Methods: From January 2010 to March 2012 twenty two consecutive patients with inoperable mCRC entered the study. Treatment schedule consist of intravenous Irinotecan 180 mg/m2 on day 1, Leucovorin 200 mg/m2 administered as intravenous infusion on day 1 and 2 and 5- Fluorouracil 400 mg/m2 bolus and Bevacizumab 5 mg/kg as an intravenous infusion with repetition every two weeks.
Results: Overall response rate was 31,9% with one complete response and six partial responses achieved. The overall survival time was 16,6 months. The main toxicities observed were leukopenia and diarrhea.
Conclusions: That data suggest that chemotherapy with Irinotecan/ 5- Fluorouracil/ Leucovorin and Bevacizumab remain reasonable regimen for the treatment of patients with mCRC.

Key words: Bevacizumab, Chemotherapy, Metastatic colorectal cancer, Survival,

- Download FULL TEXT /PDF 526 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Davidov DN. Bevacizumab Combined with Irinotecan, 5-Fluorouracil and Leucovorin as the First- line Treatment in Patients with Metastatic Colorectal Carcinoma. J of IMAB. 2014 Oct-Dec;20(6):556-559.

Correspondence to: Dr Deyan Davidov, Department of Medical Oncology, Oncological Center, Medical University, Pleven; 1, "St. Kliment Ohridsky" Str., 5000 Pleven, Bulgaria; E-mail:

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. [PubMed] [CrossRef]
2. Penna C, Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin North Am. 2002 Oct;82(5):1075-1090. [PubMed]
3. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer. 1997 Oct 1;80(7):1179-1187. [PubMed]
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first- line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000 Mar 25;355(9209):1041-1047. [PubMed] [CrossRef]
5. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl), 1999 Jul;77(7):527-543. [PubMed] [CrossRef]
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-2342. [PubMed] [CrossRef]
7. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003 Jan 1;21(1):60-65. [PubMed] [CrossRef]
8. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005 Jun 1;23(16):3697-3705. [PubMed] [CrossRef]
9. Therrase P, Arbuch S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000 Feb 2;92(3): 205-216. [PubMed] [CrossRef]
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958 Jun;53(282);457-481. Published online: 12 Apr 2012. [CrossRef]
11. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first- line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007 Oct 20;25(30):4779-86. [PubMed] [CrossRef]
12. Kopetz S, Glover K, Eng C, Wolff RA, Chang DZ, Adinin RB, et al. Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer. J Clin Oncol (Meeting Abstracts). 2007 June;25(18_suppl) abstract 4089.

Received: 28 September 2014
Published online: 23 December 2014

back to Online Journal